# Most powerful obesity drug yet: People lost up to 25% of weight in trial

> **Open Intelligence Dossier** · First detected: 2026-09-29 23:40 UTC · Category: Business

## Executive Summary
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"Most powerful obesity drug yet: People lost up to 25% of weight in trial" is generating significant coverage in the Business category, with 1 articles from 1 distinct sources tracked by PULSE so far.


Outlets currently covering the story include Reuters. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Eli Lilly | Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes | [Source Link](https://news.google.com/rss/articles/CBMiwgFBVV95cUxQZVEybVR5TEhfdXpyS29qaVM3RVBvcGY4eU1UcjdRRDJKTkRjV2F0S3p6UDFBLUVrc1J1REtGU25Tc0QzVkVydTdSZ1IyWHRCWDRBZjM5X0o1d21xSkpyQWJvWHhDNlYzMThBdlpsYkZWT1pVTUpEeTdJMDlVdm12em1QdUZXX2NIU3J0dU52QUhNNl9kOGkzc3ZMbTJXNXlfX3JybFhUZnNneTdQbnlUM0pzRWFwRlZ1OXBwc29ZR2Fldw?oc=5) |
| Reuters | Lilly's experimental drug cuts weight by 21% in diabetes trial | [Source Link](https://news.google.com/rss/articles/CBMiyAFBVV95cUxOdmJvRVgxMnhYOXRRX3pwUGtKYXZic2pPbnhZTGp5SzVHbDR3M1ZQdlRkTFc2eW1NNnh3bkduWTh1MExJTXB6dTRidXNjdVBCVHJZT3lsWXJ2TWluQ2h6Rm5kTUxadFB4RzB3cUUxWFNzVmlkcmp4WXdEb2RWYy1TZkJQOFVHbGY2RnJHOHhPbjBvdmNqeFNWYmFLVkM0SzFySmo4ZTRfZ1NvN0NzRVZlMENDNlNRSlF3Y0RiREo3MzBFSGxBdDRNaA?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-09-29/most-powerful-obesity-drug-yet-people-lost-up-to-25-of-weight-in-trial*